This fast track antibody is not yet fully characterized. It is subject to these terms and conditions

Publishing research using ab31812? Please let us know so that we can cite the reference in this datasheet.

ab31812 has been referenced in 4 publications.

  • Ahmad K  et al. Inhibition of class I HDACs abrogates the dominant effect of MLL-AF4 by activation of wild-type MLL. Oncogenesis 3:e127 (2014). ChIP . PubMed: 25402609
  • Wilkinson AC  et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep 3:116-27 (2013). WB, ChIP, CHIPseq ; Human . PubMed: 23352661
  • Geng H  et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov 2:1004-23 (2012). WB, ChIP, CHIPseq ; Human . PubMed: 23107779
  • Biswas D  et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci U S A 108:15751-6 (2011). WB ; Human . PubMed: 21896721

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"